Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KeraStat Gel is a keratin-based hydrogel wound dressing developed by KeraNetics. It is composed of human-derived keratin proteins (specifically alpha-keratins) and is designed to manage various types of wounds, including partial-thickness burns, radiation dermatitis, and surgical wounds. The gel provides a moist wound environment and a protein-rich scaffold that supports cellular migration and re-epithelialization. It has been evaluated in clinical trials for its ability to improve cosmetic outcomes and speed up healing compared to standard treatments like silver sulfadiazine. While it is regulated as a medical device, its therapeutic effect is derived from the biological properties of the keratin proteins.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on KeraStat Gel.